Barbara Schilberg JD Overview

  • Primary Position
  • Advisor

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 6

  • Med. Deal Size

  • Med. Valuation

Barbara Schilberg JD General Information

Biography

Ms. Barbara Schilberg serves as an Advisor at BioAdvance Captial. Mr. Schilberg serves as a Board Member at IO Biosciences. She served as Managing Director and Chief Executive Officer at BioAdvance. She serves as a Board Member at Keriton and Mebias Discovery. She has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as Chief Executive Officer, BioAdvance has committed $21.8 million to 31 seed-stage companies and 24 pre-seed projects focusing on areas including Alzheimer's disease, cancer, diabetes, obesity, and infectious diseases. She is a board member of Immunome, Jenrin Discovery, Marillion Pharmaceuticals, Melior Pharmaceuticals, Novira Pharmaceuticals, and QR Pharma. As a senior executive with four emerging life sciences companies, her prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements, and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for Provigil (modafinil), which the FDA approved in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation's acquisition by Advanced Medicine (now Theravance) in 2000. She also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design. She received a J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit. She served as a Board Member at Merganser Biotech.

Contact Information

Primary Position
Education
University of Virginia, JD (Doctor of Law)
Gender
Female

Barbara Schilberg JD Board Seats (6)

Company Industry Ownership Status Financing Status Location Since
ENB Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed New York, NY
IO BiO Sciences Drug Discovery Privately Held (backing) Venture Capital-Backed Doylestown, PA
Jenrin Discovery Drug Discovery Privately Held (backing) Venture Capital-Backed Chadds Ford, PA
Keriton Enterprise Systems (Healthcare) Privately Held (backing) Venture Capital-Backed Philadelphia, PA
Mebias Discovery Drug Discovery Privately Held (backing) Venture Capital-Backed Philadelphia, PA

Barbara Schilberg JD Lead Partner on Deals (42)

Barbara Schilberg JD has been the lead partner on 42 deals. Their latest deal was with Keriton, a enterprise systems (healthcare) company. The deal was made for on 14-Jun-2020.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Keriton 14-Jun-2020 Early Stage VC (Series A) Completed Enterprise Systems (Healthcare) Philadelphia, PA
Palvella Therapeutics 28-May-2020 Completed Drug Discovery Wayne, PA
ENB Therapeutics 27-Feb-2020 Completed Drug Discovery New York, NY
Palvella Therapeutics 12-Aug-2019 Completed Drug Discovery Wayne, PA
Pillo Health 29-May-2019 Completed Other Healthcare Technology Systems Boston, MA
IO BiO Sciences 04-Jan-2019 Completed Drug Discovery Doylestown, PA
Pillo Health 14-Jun-2018 Completed Other Healthcare Technology Systems Boston, MA
Jenrin Discovery 25-Apr-2018 Completed Drug Discovery Chadds Ford, PA
IO BiO Sciences 29-Mar-2018 Seed Round Completed Drug Discovery Doylestown, PA
Opsidio 31-Jan-2018 Later Stage VC Completed Drug Discovery Bryn Mawr, PA

Barbara Schilberg JD Network (200)

Board Members (63)

Name Company Representing Location From
Philip Wagenheim Immunome (acquired in 2023) Self Bothell, WA
Michael Widlitz MD Immunome (acquired in 2023) Self Bothell, WA
Immunome (acquired in 2023) BioAdvance Captial Bothell, WA
ENB Therapeutics Self New York, NY
Annovis Bio Self Malvern, PA

Portfolio Executives (133)

Name Company Role Deal date Location
Richard Mager Keriton Co-Chief Executive Officer & Board Member 14-Jun-2020 Philadelphia, PA
Roy Rosin Keriton Advisor 14-Jun-2020 Philadelphia, PA
Keriton Co-Founder, Chief Executive Officer, Chief Technology Officer, Board Member and Manager 14-Jun-2020 Philadelphia, PA
Keriton Chief Technology Officer 14-Jun-2020 Philadelphia, PA
Keriton Chief Executive Officer & President 14-Jun-2020 Philadelphia, PA

Fund Team Members (4)

Name Investor Fund Fund Location
Frederick Jones MD BioAdvance Captial Greenhouse Fund Conshohocken, PA
Gregory Harriman MD BioAdvance Captial Greenhouse Fund Conshohocken, PA
BioAdvance Captial Conshohocken, PA
BioAdvance Captial Conshohocken, PA

Barbara Schilberg JD Affiliated Funds (1)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Greenhouse Fund BioAdvance Captial Venture - General Closed 2003

Barbara Schilberg JD Advisory Roles (1)

Firm name Firm type Title Location Industry Since
BioAdvance Captial Investor Advisor Conshohocken, PA Venture Capital

Barbara Schilberg JD FAQs

  • Who is Barbara Schilberg JD?

    Ms. Barbara Schilberg serves as an Advisor at BioAdvance Captial.

  • How much does Barbara Schilberg JD typically invest?

    Barbara Schilberg JD's median deal size is .

  • What is Barbara Schilberg JD’s main position?

    Barbara Schilberg JD’s primary position is Advisor.

  • How many active board seats does Barbara Schilberg JD hold?

    Barbara Schilberg JD holds 6 board seats including ENB Therapeutics, IO BiO Sciences, Jenrin Discovery, Keriton, and Mebias Discovery.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »